🎉 Join Us at #ASPC2026! The National Triglyceride Alliance invites you to our reception at this year's @ASPCardio Congress on CVD Prevention! 📅 Friday, July 31, 2026 🕖 7:15 – 8:15 PM 📍 Salon & Patio, The Phoenician, Scottsdale, AZ Connect with clinicians, researchers, and advocates working to make triglyceride management a core part of cardiovascular care. Meet the NTA team, discover our latest educational resources, and network with colleagues at the forefront of CVD prevention. 🥂 Appetizers & refreshments served 👥 All ASPC 2026 attendees welcome — bring a colleague! RSVP optional. We can't wait to see you there! 💙 nationaltriglyceridealliance… @mmillermd1 @SethJBaumMD @EliotBrinton @lipiddoc @ArchnaBajajMD @drmaggarwal @nationallipid @foundationofnla @NatPancFdn @TGDisorders @TheAACE @HeartNurses @ArrowheadPharma @Amarincorp #CVDPrevention #Triglycerides #Cardiology

Our newest educational module: "TG Therapies Old & New and Upcoming Clinical Trials" covers the full therapeutic landscape: • Why traditional TG-lowering therapies fell short on cardiovascular outcomes despite lipid improvements • The role of remnant lipoproteins and ApoC-III–mediated pathways in residual risk • Clinical trial data on newer agents — and what's coming next • A phenotype-driven approach to matching therapy to the right patient Builds directly on the 2026 ACC/AHA dyslipidemia guidelines. 🎬 Watch free at nationaltriglyceridealliance… #Lipidology #Cardiology #Hypertriglyceridemia #CardiovascularRisk #Dyslipidemia @mmillermd1 @SethJBaumMD @EliotBrinton @lipiddoc @ArchnaBajajMD @drmaggarwal @nationallipid @foundationofnla @ASPCardio @NatPancFdn @TGDisorders @TheAACE @HeartNurses @ArrowheadPharma @Amarincorp

Check out Module 4 to update your knowledge: nationaltriglyceridealliance… @SethJBaumMD @EliotBrinton @mmillermd1 @lipiddoc @ArchnaBajajMD @drmaggarwal @nationallipid @foundationofnla @ASPCardio @NatPancFdn @TGDisorders @TheAACE @HeartNurses @ionispharma @ArrowheadPharma @Amarincorp #Triglycerides #Hypertriglyceridemia #FCS

🧠 #TrigTriviaTuesday Familial Chylomicronemia Syndrome (FCS) is caused by a deficiency in which enzyme? Drop your answer below 👇 — reveal coming in the reply!

Congratulations on 10 years of progress! We are excited for the next chapter @TGDisorders 💙

March 28 is National Triglycerides Day — a reminder for clinicians to assess and manage triglyceride-related risk. Elevated triglycerides may increase the risk of pancreatitis and cardiovascular disease. Early screening, patient education, and evidence-based interventions are key to improving outcomes. Make triglyceride management part of your clinical workflow. Featuring Seth J. Baum, MD, MASPC, FACC, FAHA, FNLA, Chairperson of the National Triglyceride Alliance and past president of the American Society for Preventive Cardiology. @SethJBaumMD @EliotBrinton @mmillermd1 @lipiddoc @ArchnaBajajMD @drmaggarwal @nationallipid @ASPCardio @NatPancFdn @livingwithfcs @TheAACE @HeartNurses @ionispharma @ArrowheadPharma @Amarincorp nationaltriglyceridealliance… #NationalTriglyceridesDay #KnowYourRisk #HeartHealth #Triglycerides #FCSAwareness

In just 12 months, the National Triglyceride Alliance has grown from an idea into a national movement advancing education, awareness, and patient support around triglyceride-related risk. From launching clinician education to uniting leading medical organizations and advocacy partners, this first year shows what’s possible when a community comes together around an unmet need. “Together we’re transforming awareness, education, and care. And we’re just getting started,” said Seth J. Baum, MD, MASPC, FACC, FAHA, FNLA, Chairperson of the National Triglyceride Alliance. Thank you for being part of the journey. Here’s to year two. @SethJBaumMD @EliotBrinton @mmillermd1 @lipiddoc @ArchnaBajajMD @drmaggarwal @nationallipid @ASPCardio @NatPancFdn @livingwithfcs @TheAACE @HeartNurses @ionispharma @ArrowheadPharma @Amarincorp nationaltriglyceridealliance… #Triglycerides #CardiometabolicHealth #MedicalEducation #Cardiology #PreventiveMedicine #HealthcareInnovation #PatientAdvocacy

One year of impact—and we’re just getting started. The National Triglyceride Alliance was founded on a simple idea: triglycerides deserve more attention as a critical driver of cardiovascular and metabolic health. Since then? ✔️ A growing national coalition ✔️ New education and clinical resources ✔️ Expanded awareness for patients and providers As we approach #NationalTriglyceridesDay (March 28), we’re reminded that progress starts with awareness—and continues with action. Let’s keep pushing forward. Read the press release: ow.ly/NPoz50YwlrN @SethJBaumMD @EliotBrinton @mmillermd1 @lipiddoc @ArchnaBajajMD @drmaggarwal @nationallipid @ASPCardio @NatPancFdn @livingwithfcs @TheAACE @HeartNurses @ionispharma @ArrowheadPharma @Amarincorp #Triglycerides #Cardiology #MedEd #HealthcareInnovation

📢 New multisociety dyslipidemia guidelines are here. The 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia brings together leading organizations to advance evidence-based care for lipid management and cardiovascular risk reduction. The updated 2026 ACC/AHA Dyslipidemia Guideline places a major new emphasis on triglycerides (TG) as both an ASCVD risk enhancer and a driver of pancreatitis risk. Here are the key takeaways: ➡️ Triglycerides matter more than ever. Elevated TG are now recognized as contributors to atherogenic remnant particles—raising ASCVD risk—starting at fasting ≥150 mg/dL or nonfasting ≥175 mg/dL. Persistent elevation is officially listed as a risk enhancer in overall cardiovascular risk assessment. ➡️ Lifestyle is the foundation of TG management. The guideline strongly reinforces that the first-line intervention for TG ≥150 mg/dL is lifestyle: lowering added sugars and refined carbs, reducing saturated fat, minimizing alcohol, adopting plant-forward dietary patterns, increasing physical activity, and aiming for 5–10% weight loss. ➡️ TG ≥500 mg/dL = elevated pancreatitis risk. Levels at or above 500 mg/dL significantly increase the risk of acute pancreatitis, with ≥1000 mg/dL demanding urgent dietary intervention and elimination of alcohol and added sugars. ➡️ Statins remain first-line for ASCVD, even with high TG. Statins reduce TG modestly (10–30%) and remain foundational for ASCVD prevention in patients with elevated triglycerides. ➡️ Additional TG‑lowering therapy for higher levels. For TG 500–999 mg/dL, adding fibrates or prescription omega‑3 fatty acids is reasonable to reduce pancreatitis risk. For ≥1000 mg/dL, these therapies become even more critical, along with strict dietary fat restriction. ➡️ A major update: Olezarsen for FCS. For patients with familial chylomicronemia syndrome (FCS) and TG ≥1000 mg/dL, the guideline recommends Olezarsen, an apoC‑III inhibitor shown to significantly lower TG and reduce pancreatitis episodes. ➡️ Referral to an RDN is now a Class 1 recommendation. For TG ≥1000 mg/dL—and even TG 150–999 mg/dL with CKM syndrome—working with a Registered Dietitian Nutritionist is strongly recommended to tailor nutrition therapy. jacc.org/doi/10.1016/j.jacc.… @SethJBaumMD @EliotBrinton @mmillermd1 @lipiddoc @ArchnaBajajMD @drmaggarwal @nationallipid @ASPCardio @NatPancFdn @livingwithfcs @TheAACE @HeartNurses @ionispharma @ArrowheadPharma @Amarincorp

@SethJBaumMD @EliotBrinton @lipiddoc @ArchnaBajajMD @drmaggarwal @nationallipid @ASPCardio @NatPancFdn @livingwithfcs @TheAACE @HeartNurses @ionispharma @ArrowheadPharma @Amarincorp